EW vs SYK
Edwards Lifesciences and Stryker Corporation, both Healthcare
Stryker Corporation is the larger company at $120B against $50B. On trailing earnings SYK is the cheaper of the two at a P/E of 28.7 against 49.0, a gap that is only a bargain if the two are growing at similar rates. Over the past year EW returned +14% against -26% for SYK. The RyuScore puts SYK ahead, 66 against 60 out of 100.
| Figure | EW | SYK |
|---|---|---|
| Last close | $85.20 | $277 |
| Market cap | $50B | $120B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 49.0 | 28.7 |
| 1-year return | +14% | -26% |
| 5-year return | -29% | +7.6% |
| RyuScoresector-relative, 1–10 | 60/100 | 66/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Edwards Lifesciences
Revenue of $1.7B in Q2 2026, net income $241M. Its largest reported line is Transcatheter Aortic Valve Replacement, 72% of the disclosed total.
Stryker Corporation
Revenue of $6.6B in Q2 2026, net income $1.3B. Its largest reported line is Traumaand Extremities, 16% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.